Maternal and fetal outcomes in patients with systemic lupus erythematosus

Objectives: Lupus is associated with a considerable risk of fetal and maternal complications. The aim of this study was to assess the maternal and fetal outcomes in pregnant women with systemic lupus erythematosus (SLE) and likely predictors of adverse outcome in Benghazi, Libya. Patients and Methods: This was a retrospective review of the outcome of sixty pregnancies among 48 SLE patients attending the rheumatology clinics at Benghazi medical center, who were pregnant from January 2008 to December 2018. Each pregnancy was counted as a separate case. Results: The mean age to conceive was 30.6±6.1 years (19–42 years). Nineteen (31.7%) patients were primigravida, and the patients' age at SLE diagnosis was 25.2 ± 5.6 years. Forty-eight of the pregnancies (80%) were planned, ten patients have preexisting hypertension (HTN), most cases were in clinical remission before pregnancy (53 patients; 88%), only seven patients were identified as having active disease, four of them had lupus nephritis based on clinical features. Secondary antiphospholipid syndrome was diagnosed in four patients. Most pregnancies (50; 83%) resulted in live birth babies, 3 (5%) of them were preterm due to preeclampsia, six pregnancies (10%) ended in spontaneous abortion, and there were four intrauterine fetal deaths. More positive cases for aCl antibodies were affected than negative cases (P = 0.005). Five pregnancies complicated by preeclampsia, three of them have preexisting HTN, thirty patients (50%) underwent vaginal delivery, twenty patients (33%) underwent cesarean section due to different obstetric indications (previous cesareans and preeclampsia). Thirteen neonates (26%) were born with low birth weight, and two neonates (3%) required neonatal intensive care unit admission; no neonatal cases of lupus or congenital cardiac problems were reported. Postnatal SLE flare was reported among 16 patients (53%); preexisting HTN was strongly associated with preeclampsia, preterm labor, and postnatal SLE flares (P-values were 0.001, 0.003, and 0.004, respectively), whereas secondary Antiphospholipid antibody syndrome (APL) was associated with preeclampsia and abortion (P = 0.005 and 0.002). Conclusion: Preexisting HTN and secondary APL are associated with an increased risk of pregnancy complications. Characteristics and outcomes in our series are comparable to previously published international cohorts.

Key-words:

Fetal outcomes - intrauterine fetal deaths - Libya - maternal - pregnancy - spontaneous abortion - systemic lupus erythematosus

Introduction

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease that mainly affects women in the reproductive age group. SLE females have the same fertility rate as the age-matched population of healthy females.[[1]],[[2]]

A better understanding of the pathogenesis of SLE and good use of immunosuppressive drugs allowed better control of the disease activity resulting in a remarkable improvement in the quality of life of these patients, including pregnancy outcomes.[[3]],[[4]] Nevertheless, there is still a considerable risk of fetal and maternal complications.[[5]] Pregnancies for patients with SLE have a higher risk of fetal loss, intrauterine growth retardation (IUGR), prematurity, preeclampsia, higher mortality risk, and low birth weight (LBW) in addition to an increase in the disease activity itself.[[6]],[[7]] Most of these complications are often difficult to distinguish from physiological changes or complications arising from pregnancy.[[7]]

There are limited data on SLE in pregnancy in our part of the world and the aim of this study was to assess adverse pregnancy outcomes and their likely predictors in women with SLE in Benghazi, Libya.

Patients and Methods

This was a retrospective cohort study of sixty pregnancies in 48 SLE female patients attending the rheumatology clinics at Benghazi Medical Center (Benghazi, Libya), whom conceived during the period of January 2008–December 2018. Each pregnancy was counted as a separate episode (case). All patients were >18 years' old and fulfilled at least 4 of the 11 criteria of the American College of Rheumatology.[[8]] Antiphospholipid syndrome (APS) was diagnosed according to the 2006 revised classification criteria.[[9]] Data collected included age, gravidity, parity, age at SLE diagnosis, duration of disease, pre- and postnatal SLE manifestations, current and past medications utilized, lupus activity before and after conception, and laboratory data. Investigations included antinuclear antibodies, anti-double-stranded DNA (dsDNA) antibodies, lupus anticoagulants, anticardiolipin antibodies via immunoglobulins G (aCL IgG) and M (aCL IgM). Anti-Ro/SSA and anti-La/SSB antibodies were also collected. Baseline routine laboratory tests (prenatal, natal, and postnatal) included complete blood picture, serum transaminases, alkaline phosphatase, serum albumin, creatinine, urine analysis, 24-h urine collection for total proteinuria, fasting and postprandial blood glucose, serum uric acid, and erythrocyte sedimentation rate were collected.

Pregnancy outcomes were assessed by the occurrence of obstetric complications including spontaneous abortion (a miscarriage in which the fetus is born before the 20th week of pregnancy), intrauterine fetal death (IUFD)(defined as fetal death at or after 20–28 weeks of pregnancy), IUGR (defined as fetal weight that is below the 10th percentile for gestational age as determined through an ultrasound), development of preeclampsia (defined as new-onset hypertension (HTN) and proteinuria after 20 weeks' gestation), preterm labor (before 37 weeks' gestation), and postnatal SLE flare. Neonatal outcome was assessed by live births (term and preterm), LBW (<2.5 kg at birth), neonatal deaths (within 28 days after delivery), neonatal lupus syndrome or congenital heart block, and admission to neonatal intensive care unit (NICU).

The disease activity of SLE was evaluated using the SLE disease activity index (SLEDAI). Active disease at conception was defined as the SLEDAI score + or > 2.[[10]] SLE flare was defined as worsening of disease during pregnancies or development of new manifestations. Fares included new or worsened cutaneous disease, arthritis, pleuritis, pericarditis, nephritis, hematological abnormalities as hemolytic anemia or platelet count below 60,000/lL, adding new drugs (hydroxychloroquine and/or azathioprine), hospitalization for SLE-related manifestations, and increased prednisone dose.

Descriptive statistics were used to summarize the data. Chi-square test was used to evaluate the impact of clinical and laboratory characteristics on maternal and fetal outcomes. Logistic analysis was used to study the predictors of adverse pregnancy outcome (defined as the occurrence of abortion, preeclampsia, prematurity, IUFD, or SLE flare). Each pregnancy was considered as a separate observation. In all cases, P < 0.05 was considered to be statistically significant. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) 17.0 (SPSS; SPSS Inc., Chicago, IL, USA).

Results

We reviewed data of 78 cases; 18 were excluded from the study because of missing data about pregnancy, natal and postnatal clinical condition. The mean age of the patients at getting pregnant was 30.6 ± 6.1 years (19–42 years). Nineteen (31.7%) were primigravida, and 41 (68.3%) were multigravida. The duration of SLE before pregnancy was 8 ± 4.3 years (1.5–21 years). Patient's age at SLE diagnosis was 25.2 ± 5.6 years. Forty-eight pregnancies (80%) were planned, ten patients have preexisting HTN, most cases were in clinical remission before pregnancy as determined by SLEDAI index (53 patients; 88%), the other seven patients were labeled as active disease, and four of them have lupus nephritis. Secondary antiphospholipid syndrome was diagnosed in four patients. Forty patients were on oral prednisolone with dose less than 25 mg/day which was markedly reduced to <10 mg/day among 51 patients, most patients continue on fixed dose hydroxychloroquine 200 mg/day pre and postnatally, and there were 55 patients on azathioprine 100 mg/day that continued pre and postnatally on the same dose. Two patients were on intravenous pulse cyclophosphamide therapy 3 months before conception which was stopped during pregnancy, the number increased to seven patients postnatally; SLE clinical manifestations as well as medications pre and postnatal and autoantibodies profile are shown in [[Table 1]].

Table 1: Clinical characteristics of the study population

Most pregnancies (50; 83%) resulted in live birth babies, three (5%) of them were preterm due to preeclampsia, six pregnancies (10%) ended by spontaneous abortion, and there were four IUFD, most of them were positive for aCl antibodies (P = 0.003 compared to patients with negative aCl antibodies).

Five pregnancies were complicated due to preeclampsia, in which three of them have preexisting HTN, 30 patients (50%) underwent vaginal delivery, and 20 patients (33%) underwent cesarean section due to different obstetric indications (previous cesareans, preeclampsia).

Thirteen neonates (26%) were born with LBW, and two neonates (3%) required NICU admission; there were no neonatal cases of lupus or congenital cardiac problems.

Postnatal SLE flare (occurs within three months after delivery) was reported among 16 patients, 8 of them developed nephritis based on clinical findings of hematuria, raised renal function test, and low complements level; renal biopsy was not done because it is not easily accessible in our country, except for one patient whom renal biopsy resulted in class III lupus nephritis; there was one patient developed severe serositis in the form of pericarditis and infective endocarditis confirmed by echocardiographic findings and cultures.

Preexisting HTN was strongly associated with preeclampsia, preterm labor, and postnatal SLE flares (P = 0.001, 0.003, and 0.004, respectively), whereas secondary APL was associated with preeclampsia and abortion (P = 0.005 and 0.002).

Discussion

We retrospectively reviewed sixty pregnancies, of which 47 pregnancies (78%) ended without major maternal or fetal complications. Our study showed that spontaneous abortion occurred in six pregnancies (10%). This is less than some other studies such as Eman et al.[[11]] in their review of 91 pregnancies in Egypt reported that spontaneous abortion was recorded in 15%; but slightly higher than another multicenter study conducted by Moroni et al.[[12]] which showed an incidence of 8.4%. Previously reported abortion incidence varied between 4% and 28%.[[11]],[[12]],[[13]],[[14]]

In our study, the incidence of preterm labor was 5%, which is much low compared to that observed in a neighboring country reported by Eman et al.[[11]] in which incidence of priority was 13%. Other studies reported a wide range in priority incidence between 17% and 54%.[[15]],[[16]]

Five pregnancies in the present study were complicated by preeclampsia, three of them have preexisting HTN (P = 0.001) and secondary APL (P = 0.005). Other retrospective studies reported a wide range of preeclampsia incidence 3%–26% in which HTN was demonstrated as a significant risk factor.[[11]],[[17]]

There were no reported SLE flares during pregnancy in our cohort. However, SLE flare was reported among 16 cases (26.6%) within 3 months after delivery, 8 of them (10%) develop nephritis, and one patient developed severe serositis in the form of pericarditis and infective endocarditis.

Although there is still uncertainty about the exact effect of pregnancy on the course of SLE, several studies showed that pregnancy increaseds the incidence of SLE flares with rates up to 35%,[[18]],[[19]] whereas others reported no difference.[[20]] A multicenter prospective trial assessing maternal outcomes of pregnant women with slightly active or inactive lupus nephritis before pregnancy reported that mild-to-moderate disease flares occurred in 18.3% and severe flares in 1.4% of pregnancies;[[21]] these findings were slightly higher than ours mentioned.

Adverse pregnancy outcomes were significantly associated with HTN and APL. In the present study, preexisting HTN was strongly associated with preeclampsia, preterm labor, and postnatal SLE flares (P = 0.001, 0.003, and 0.004, respectively), whereas secondary APL was associated with preeclampsia and abortion (P = 0.005 and 0.002). Older age at pregnancy and active disease before pregnancy were associated in our patients with increased risk of postnatal SLE flares (P = 0.004); some previous studies demonstrate that SLE patients with APS had almost two-fold increase in fetal loss when compared to SLE patients with negative APS,[[22]] although other studies correlated active lupus nephritis and younger maternal age to prematurity.[[21]]

Conclusion

Despite the improvements in pregnancy outcome of SLE pregnant patients, there is still adverse maternal and fetal outcomes. Preexisting HTN and secondary APL are associated with an increased risk of pregnancy complications. Our data are close to the generally reported in all the previous studies. There is an urgent need to further reduce the risk of lupus during pregnancy by implementing high-risk pregnancy clinics to ensure close monitoring and timely interventions.

Authors' contribution

Equal contribution.

Compliance with ethical principles

The study was conducted according to the Declaration of Helsinki 1975. The study was approved by the scientific committee at Jamhorya hospital [INSIDE:1]. All the information was kept confidential, and no individual identifiers were collected.

Conflict of Interest

There are no conflicts of interest.

Acknowledgments

We would like to thank all our patients who cooperated in data collection of this research.

Financial support and sponsorship

Nil.

• References

• 1 Østensen M. New insights into sexual functioning and fertility in rheumatic diseases. Best Pract Res Clin Rheumatol 2004;18:219-32.
• 2 Lateef A, Petri M. Systemic lupus erythematosus and pregnancy. Rheum Dis Clin North Am 2017;43:215-26.
• 3 Ravelli A, Ruperto N, Martini A. Outcome in juvenile onset systemic lupus erythematosus. Curr Opin Rheumatol 2005;17:568-73.
• 4 Pastore DE, Costa ML, Parpinelli MA, Surita FG. A critical review on obstetric follow-up of women affected by systemic lupus erythematosus. Rev Bras Ginecol Obstet 2018;40:209-24.
• 5 Cervera R, Font J, Carmona F, Balasch J. Pregnancy outcome in systemic lupus erythematosus: Good news for the new millennium. Autoimmun Rev 2002;1:354-9.
• 6 Clark CA, Spitzer KA, Nadler JN, Laskin CA. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol 2003;30:2127-32.
• 7 Yamamoto Y, Aoki S. Systemic lupus erythematosus: Strategies to improve pregnancy outcomes. Int J Womens Health 2016;8:265-72.
• 8 Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
• 9 Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
• 10 Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
• 11 Eman A, Hussein A, Rafaat M, Abeer N. Mokbel pregnancy outcome in patients with systemic lupus erythematosus: A single center study in the high risk pregnancy unit. Middle East Fertil Soc J 2016;21:168-174.
• 12 Moroni G, Doria A, Giglio E, Tani C, Zen M, Strigini F, et al. Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. J Autoimmun 2016;74:6-12.
• 13 Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010;5:2060-8.
• 14 Buyon JP, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD, et al. Predictors of pregnancy outcome in a prospective, multiethnic cohort of lupus patients. Ann Int Med 2015;163:153-163.
• 15 Chakravarty EF, Colón I, Langen ES, Nix DA, El-Sayed YY, Genovese MC, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol 2005;192:1897-904.
• 16 Chen D, Lao M, Zhang J, Zhan Y, Li W, Cai X, et al. Fetal and Maternal Outcomes of Planned Pregnancy in Patients with Systemic Lupus Erythematosus: A Retrospective Multicenter Study. J Immunol Res 2018;2018:2413637.
• 17 Cavallasca JA, Laborde HA, Ruda-Vega H, Nasswetter GG. Maternal and fetal outcomes of 72 pregnancies in Argentine patients with systemic lupus erythematosus (SLE). Clin Rheumatol 2008;27:41-6.
• 18 Imbasciati E, Tincani A, Gregorini G, Doria A, Moroni G, Cabiddu G, et al. Pregnancy in women with pre-existing lupus nephritis: Predictors of fetal and maternal outcome. Nephrol Dial Transplant 2009;24:519-25.
• 19 Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005;52:514-21.
• 20 Tandon A, Ibañez D, Gladman DD, Urowitz MB. The effect of pregnancy on lupus nephritis. Arthritis Rheum 2004;50:3941-6.
• 21 Moroni G, Doria A, Giglio E, Imbasciati E, Tani C, Zen M, et al. Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. J Autoimmun 2016;74:194-200.
• 22 Cortés-Hernández J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: A prospective study of 103 pregnancies. Rheumatology (Oxford) 2002;41:643-50.

Publikationsverlauf

Eingereicht: 31. Januar 2020

Angenommen: 13. Januar 2020

Artikel online veröffentlicht:
07. Juli 2022